work areas

The Medicines Evaluation Board (MEB) evaluates and monitors the efficacy, risks and quality of:


Human Medicinal Products
The Medicines Evaluation Board is responsible for authorising and monitoring safe and effective medicinal products on the Dutch market and shares in responsibility for authorising medicinal products throughout the European Union. Before a medicinal product can be sold in the Netherlands, it has to receive marketing authorisation from the MEB. The MEB evaluates the medicinal product and decides on the conditions under which it can be placed on the Dutch market. It also decides on the product's legal status (whether it can be obtained without prescription or whether it may only be dispensed on prescription).

If you would like more information about this area of activity (human medicinal products), click on 'Topics on work areas' on the menu to the right.

Veterinary Medicinal Products
The Medicines Evaluation Board assesses veterinary medicinal products (medicines for animals) as well as human medicinal products. The MEB's Veterinary Medicinal Products Unit is responsible for assessing and authorising veterinary medicinal products for both the Dutch and European markets and for monitoring veterinary medicinal products once they have been granted marketing authorisation.

If you would like more information about this area of activity (veterinary medicinal products), click on 'Topics on work areas' on the menu to the right.

Novel foods
The Medicines Evaluation Board assesses novel foods as well as medicinal products. Before a novel food is placed on the market, it has to be scientifically assessed to make sure that it is safe for consumers. Novel foods are assessed by the MEB's Novel Foods Unit.

If you would like more information about this area of activity (novel foods), click on 'Topics on work areas' on the menu to the right.

Back